The Hyderabad-based pharmaceutical company, Zydus Cadila; will soon roll out its Covid vaccine in the Indian market. It is specially manufactured for children and young adults. So far, Covaxin and Covishield are two vaccines dominating in India. Bharat Biotech’s Covaxin is also in its children’s trial phase. Serum Institute of India’s Covishield; is more widely used. Russian Sputnik-V; is also available in some regions across the country.
COVID-19 Jabs by Zydus Cadila to Roll Out in the Market Soon
Zydus Cadila, a Hyderabad-based pharma company; is coming up with its COVID-19 vaccine. It is especially getting approved for children between 12 to 18 years.
The central government presented an affidavit; to the Supreme Court on Saturday. However, the Supreme Court raised several questions; to which the Centre responded accurately. Currently, Covishield and Covaxin are in regular use in India. Besides that, Russia’s Sputnik-V is also available in several regions. The central government has also briefed; its vaccination plans to the Supreme Court. On the other hand, the Supreme Court also enquired; about the overhaul in the vaccination policy earlier this month.
What did the Central Government Say to the Supreme Court?
The central government; has shared its vaccination plans with the Supreme Court. It mentioned that they need 186.6 crore vaccine doses; to vaccinate people above 18 years. According to the Centre, these people are 93-94 crores in number. Besides that, it also mentioned that walk-in vaccinations; are permitted for all ages now. People need not do any prior registration to get vaccinated. The central government has called its vaccination policy; dynamic and not static. Under the new vaccination policy; vaccination is free for all above 18 years. Currently, people can get vaccinated with Covishield and Covaxin. Zydus Cadila will also roll out its vaccines soon in the market.
What is Supreme Court’s Concern?
The New Covid variant, Delta Plus is spreading in India. So far, India has not even vaccinated; half of its population. Only 5.6 per cent of India’s total population; has received both doses. The Supreme Court called the Centre’s paid vaccine policy; “arbitrary and irrational”. It also mentioned several other flaws; such as vaccine shortage and unavailability. Besides Zydus Cadila, Covaxin is also conducting trials for children’s vaccine. Most probably, it will wrap up its trial in September this year.
